Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation

Stanford University

Status: Enrolling

Conditions: Blood and Marrow Transplant (BMT)

Study type: Observational

Funder types: Other

Identifiers

NCT01629017

IRB-4134

Details and patient eligibility

About

This project allows for the systematic collection and analysis of long-term follow-up clinical parameters in children who have received a stem cell transplant. The data collected will assist in determining appropriate intervention and treatment plans for patients enrolled on this study. In addition, future patients may benefit by having the ability to anticipate problems and develop methods of prevention or early intervention.

Full description

Primary Objective: Implement long-term follow-up guidelines for children, adolescents and young adults who are survivors of HSCT while establishing a database which captures the survivor's lifetime care.

Secondary Objectives:

• Collect evidence-based data through a structured framework of periodic physical examination, laboratory and medical tests to monitor late effects in our HSCT survivors.
• Establish standards of care for late effects of therapy post HSCT for malignant and non-malignant diagnoses.
• Provide early identification and intervention towards recognized problems, as well as consistent education to foster a healthy lifestyle to all survivors.
• Collect blood and tissue samples to study immune reconstitution of all immune cell types and learn more about immune reconstitution and its affect on post-HSCT complications and disease free survival.

Enrollment: 800 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant is scheduled to receive OR has received a hematopoietic stem cell transplant (HSCT) for any condition.
• Participant may have had a HSCT in another institution than Lucile Packard Children's Hospital (LPCH) yet has transferred follow-up long-term care to our institution and is being seen through the late-effects clinic from the Pediatric HSCT program.
• Participant AND/OR parent/legally authorized representative is able to provide written informed consent and assent (as applicable) for participation.

Exclusion criteria

• Participant has relapsed from a malignant diagnosis post HSCT and is not being worked-up for a new HSCT.
• Participant or patient's authorized guardian is unable to provide consent and assent